Wei A. He
Impact in
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Research top 2%
- MicroRNA in disease regulation
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
Papers in
- Hepatology 42
- Hepatocellular Carcinoma Treatment and Prognosis 42
-
- MicroRNA in disease regulation 8
- Co-authors
- Yunfei Yuan (40 shared papers)Binkui Li (39 shared papers)Jiliang Qiu (36 shared papers)Denis C. Guttridge D (3 shared papers)Yun Zheng (24 shared papers)Ruhai Zou (20 shared papers)Chenwei Wang (18 shared papers)Dinglan Zuo (16 shared papers)
- Journals
- BMC Cancer (3 papers)癌症：英文版 (3 papers)HemaSphere (3 papers)Journal of Cancer (3 papers)Surgery (2 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Wei A. He
117 papers receiving 3.4k citations
Wei A. He's Hit Papers
Peers
Comparison fields: 5 of 114
- Hepatology 755
- Cancer Research 583
- Molecular Biology 996
- Oncology 274
- Pulmonary and Respiratory Medicine 364
Countries citing papers authored by Wei A. He
This map shows the geographic impact of Wei A. He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei A. He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei A. He more than expected).
Fields of papers citing papers by Wei A. He
This network shows the impact of papers produced by Wei A. He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei A. He. The network helps show where Wei A. He may publish in the future.
Co-authors
The 25 scholars most cited alongside Wei A. He, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 125 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer Hit paper breakdown → | 2016 | 415 |
| 2 | 2013 | 299 | |
| 3 | 2014 | 221 | |
| 4 | 2017 | 133 | |
| 5 | 2015 | 114 | |
| 6 | 2010 | 110 | |
| 7 | Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study Hit paper breakdown → | 2023 | 96 |
| 8 | 2014 | 94 | |
| 9 | 2018 | 80 | |
| 10 | 2020 | 74 | |
| 11 | 2006 | 70 | |
| 12 | 2008 | 69 | |
| 13 | 2013 | 65 | |
| 14 | 2023 | 65 | |
| 15 | 2021 | 63 | |
| 16 | 2022 | 63 | |
| 17 | 2021 | 59 | |
| 18 | 2016 | 56 | |
| 19 | 2019 | 54 | |
| 20 | 2014 | 52 |
About Wei A. He
Wei A. He is a scholar working on Hepatology, Cancer Research, Oncology, Molecular Biology and Hematology, having authored 125 papers that have together received 3.5k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (42 papers), MicroRNA in disease regulation (8 papers), Cardiovascular Function and Risk Factors (5 papers), Multiple Myeloma Research and Treatments (4 papers), Cancer Immunotherapy and Biomarkers (3 papers), 2D Materials and Applications (3 papers), Tuberculosis Research and Epidemiology (3 papers) and Colorectal Cancer Treatments and Studies (3 papers). The work is most often cited by research in Hepatology (755 citations), Cancer Research (583 citations), Molecular Biology (996 citations), Oncology (274 citations) and Pulmonary and Respiratory Medicine (364 citations). Wei A. He has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Yunfei Yuan, Binkui Li, Jiliang Qiu, Denis C. Guttridge D, Yun Zheng, Ruhai Zou, Chenwei Wang, Dinglan Zuo, Priya Londhe and Alessandro Canella. Their work appears in journals such as BMC Cancer, 癌症：英文版, HemaSphere, Journal of Cancer and Surgery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.